<DOC>
	<DOCNO>NCT02144675</DOCNO>
	<brief_summary>This randomized phase II trial study well choline magnesium trisalicylate idarubicin cytarabine work treat patient acute myeloid leukemia . Drugs use chemotherapy , choline magnesium trisalicylate , idarubicin , cytarabine , work different way stop growth cancer cell , either kill cell stop dividing . It yet know whether choline magnesium trisalicylate combination chemotherapy effective combination chemotherapy alone treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Choline Magnesium Trisalicylate Combination Chemotherapy Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine temporal change leukemic cell nuclear factor kappa light chain enhancer B-cells 1 ( NF-kB ) activity salicylate ( choline magnesium trisalicylate ) administer patient acute myeloid leukemia ( AML ) induction chemotherapy . II . To determine toxicity associate administration salicylate set induction chemotherapy . III . To determine salicylate alters expression NF-kB-regulated gene AML cell . IV . To determine NF-kB modulation salicylate alters AML chemotherapy drug efflux . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive choline magnesium trisalicylate orally ( PO ) every 8 hour day 0-7 , idarubicin intravenously ( IV ) day 1-3 , cytarabine IV continuously day 1-7 . ARM II : Patients receive idarubicin IV day 1-3 cytarabine IV continuously day 1-7 . In arm , treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Choline</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<mesh_term>Choline magnesium trisalicylate</mesh_term>
	<criteria>Patients must diagnosis nonM3 AML ( patient M3 subtype exclude ) ; determination presence cytogenetic abnormality standard cytogenetics +/ fluorescentinsitu ( FISH ) study ; additional molecular analysis nucleophosmin ( NPM ) mutation fmsrelated tyrosine kinase 3 ( flt3 ) internal tandem duplication obtain part standard care institutional procedure Leukemic blast count &gt; 1500/mm^3 peripheral blood Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 3 Total bilirubin &lt; 2 time institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) &lt; 3 time institutional ULN Serum creatinine &lt; 1.5 time institutional ULN Multi gate acquisition scan ( MUGA ) echocardiogram leave ventricular ejection fraction ( LVEF ) &gt; 50 % Women childbearing potential must negative pregnancy test No uncontrolled psychiatric illness principal investigator feel compromise obtain informed consent patient Patient must inform investigational nature study must give write informed consent accordance institutional federal guideline ; patient provide informed consent eligible study Any coexist medical condition medication preclude full compliance arm study Allergies investigational drug and/or chemotherapeutic agent Allergies nonsteroidal antiinflammatory drug ( NSAIDs ) /salicylates ( e.g. , aspirin ) Endoscopically document upper low gastrointestinal ( GI ) relate hemorrhage within last 6 month ; also , patient clinical diagnosis GI bleed require blood transfusion exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>